14 Hodgkin's Lymphoma 1 1 0 15 15 256 http://clinicaltrials.dfhcc.harvard.edu/trials/256 Tacrolimus/Sirolimus/Methotrexate Versus Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma This trial is comparing whether using a drug called sirolimus for graft versus host disease (GVHD) prevention can decrease the chance of the participant's lymphoma relapsing after transplantation, compared to using a standard GVHD prevention regimen without sirolimus. Since mTOR inhibitors have anti-lymphoma activity, their use after transplantation may lead to a decreased risk of relapse and hence better transplantation outcome. Recruiting 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma 14 Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/14-hodgkin-s-lymphoma Phase 3 15 http://clinicaltrials.dfhcc.harvard.edu/trials/15 Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma The purpose of this research study is to determine the effectiveness and safety of Avastin when combined with standard chemotherapy for Hodgkin lymphoma. Avastin works differently than standard chemotherapy drugs. It is a type of protein called an antibody which binds to a substance called VEGF(Vascular Endothelial Growth Factor). VEGF stimulates the growth of the blood vessels that feed tumors and encourages tumor cell growth. VEGF is produced in excess by Hodgkin lymphoma cells, and is associated with a poorer outcome in patients with Hodgkin lymphoma. When the activity of VEGF is interrupted in multiple other cancer types, the blood vessels around the tumor cells die resulting in less nutrient delivery and death to the tumor. Blocking of VEGF has also been shown to improve delivery of chemotherapy to cancer cells, making standard chemotherapy work better. This trial uses Avastin in combination with standard chemotherapy with the goal of improving the cure rate over chemotherapy alone. Recruiting 14 Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/14-hodgkin-s-lymphoma Phase 2 327 http://clinicaltrials.dfhcc.harvard.edu/trials/327 Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies This is a Phase 1/2a, non-randomized, open-label, multi-center study designed to determine the Maximum Tolerated Dose (MTD) of Pralatrexate Injection and Gemcitabine with vitamin B12 and folic acid supplementation to patients with relapsed or refractory lymphoproliferative malignancies. Recruiting 14 Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/14-hodgkin-s-lymphoma 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma Phase 1/Phase 2 337 http://clinicaltrials.dfhcc.harvard.edu/trials/337 Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies This study is to evaluate the highest tolerated dose, safety and activity of HCD122 in adults with non-Hodgkin's or Hodgkin's lymphoma who have received at least two prior therapies. Recruiting 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma 14 Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/14-hodgkin-s-lymphoma Phase 1/Phase 2 362 http://clinicaltrials.dfhcc.harvard.edu/trials/362 A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies The Phase 1 portion of the study will evaluate the pharmacokinetic profile and safety of ABT-263 with the objective of defining the dose limiting toxicity and maximum tolerated dose. The Phase 2a portion of the study will evaluate ABT-263 at the defined recommended Phase 2 dose to obtain additional safety information and a preliminary assessment of efficacy. Recruiting 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma 14 Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/14-hodgkin-s-lymphoma Phase 1/Phase 2 7 http://clinicaltrials.dfhcc.harvard.edu/trials/7 Reduced Intensity, Sequential Double Umbilical Cord Blood Transplantation Using Prostaglandin E2 (PGE2) The purpose of this research study is to determine the effects of 16, 16 Dimethyl-Prostaglandin E2 (dmPGE2) treatment on umbilical cord blood units to be used in transplantation. dmPGE2 treatment is being tested to see if it can improve the ability of umbilical cord blood stem cells to grow after transplantation. The growth of stem cells after transplantation is sometimes referred to as "engraftment". One of the major problems after umbilical cord transplantation is the time required for engraftment. After transplantation of two umbilical cord blood units, the average time to achieve engraftment is 21 days. In addition, up to 10% of patients who undergo umbilical cord blood transplantation never engraft, a potentially life-threatening condition. In laboratory studies, treatment of umbilical cord blood stem cells with dmPGE2 was shown to enhance engraftment. Recruiting 14 Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/14-hodgkin-s-lymphoma 17 Multiple Myeloma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/17-multiple-myeloma 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma 11 Leukemia/MDS http://clinicaltrials.dfhcc.harvard.edu/diagnoses/11-leukemia-mds Phase 1 129 http://clinicaltrials.dfhcc.harvard.edu/trials/129 Infusion of Donor Lymphocytes Depleted of CD25+ Regulatory T-Cells in Patients With Relapsed Hematologic Malignancies The purpose of this research study is to evaluate the safety and efficacy of cell depletion in a donor lymphocyte infusion (DLI) product with the use of the CliniMACS machine. Previously, patients with hematologic malignancies who have relapsed after transplant have been given infusions of donor white blood cells calsed donor lymphocyte infusion (DLI) as a way to boost their immune function and fight cancer. Information from other research studies suggests that lowering the number of a certain type of white blood cell called CD25+ Tregs in the DLI may allow for a greater effect. In this research study, we are looking for the appropriate dose of DLI depleted of the CD25+ Treg white blood cells that can be given safely. Recruiting 17 Multiple Myeloma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/17-multiple-myeloma 11 Leukemia/MDS http://clinicaltrials.dfhcc.harvard.edu/diagnoses/11-leukemia-mds 14 Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/14-hodgkin-s-lymphoma 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma Phase 1 921 http://clinicaltrials.dfhcc.harvard.edu/trials/921 Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant The proposed study is based on our observation of paradoxical tumor regression after rejection of the donor graft in conjunction with the results of our murine experiments. We hypothesize that clinically meaningful responses can be achieved in patients with advanced malignancies with a transplant strategy using nonmyeloablative conditioning and related mismatched donor stem cell transplant where the intention will be to initially achieve mixed chimerism which will be followed by recipient lymphocyte infusion (RLI) in an attempt to deliberately reject the donor graft. This will lead to the development of novel transplant strategies for achieving antitumor effects without the risk of graft versus host disease (GVHD). This proposed protocol is a Pilot Study that will evaluate the safety of this outpatient transplant strategy, i.e., establishment of initial mixed chimerism followed by RLI for donor graft rejection, in patients with advanced lymphomas, and multiple myeloma. In addition, because RLI have been reported to reverse ongoing GVHD, this approach might potentially reverse GVHD while achieving antitumor responses if this complication unexpectedly occurs. Recruiting 14 Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/14-hodgkin-s-lymphoma 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma 17 Multiple Myeloma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/17-multiple-myeloma Phase 1 75 http://clinicaltrials.dfhcc.harvard.edu/trials/75 Breast MRI Screening in Women Treated With Mediastinal Irradiation for Hodgkin's Disease The purpose of this study is to determine if the use of breast MRI in detecting breast malignancies in survivors of Hodgkin's disease is more successful than the traditional mammogram. Recruiting 14 Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/14-hodgkin-s-lymphoma 3 Breast Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/3-breast-cancer N/A 104 http://clinicaltrials.dfhcc.harvard.edu/trials/104 Procurement of Follicular B Cell Lymphoma Cells for the Purpose of Possible Use in Future Clinical Trials In order to learn more about follicular lymphoma and anti-cancer vaccines, we are collecting samples from people with this diagnosis. We then hope to make a vaccine from this tissue to help the immune system destroy cancer cells. We plan on keeping samples in the tissue bank indefinitely. Recruiting 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma 14 Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/14-hodgkin-s-lymphoma N/A 237 http://clinicaltrials.dfhcc.harvard.edu/trials/237 Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin's Disease This research study is being done because patients with a history of chest radiation treatment for Hodgkin's disease have been shown to be at increased risk for developing lung cancer a number of years out from treatment. The risk appears to be further increased among patients with a smoking history. Currently, the practice is to recommend annual low-dose chest CT scans in survivors of Hodgkin's disease who have received prior chest radiation treatment and who have at least a moderate smoking history. In this study, the CT scans will be read and interpreted by the study radiologist, and the results recorded in a consistent manner. Recruiting 14 Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/14-hodgkin-s-lymphoma 13 Lung Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/13-lung-cancer N/A 311 http://clinicaltrials.dfhcc.harvard.edu/trials/311 Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies The purpose of this study is to investigate possible genetic factors that contribute to the development of lymphomas. The databank will be used to determine whether familial lymphomas have unique genetic characteristics different from sporadic lymphomas and to attempt to identify a gene that confers an increased risk of lymphoma. Recruiting 17 Multiple Myeloma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/17-multiple-myeloma 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma 14 Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/14-hodgkin-s-lymphoma 11 Leukemia/MDS http://clinicaltrials.dfhcc.harvard.edu/diagnoses/11-leukemia-mds N/A 1232 http://clinicaltrials.dfhcc.harvard.edu/trials/1232 Phase II Study of Oral Panobinostat in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma This study will evaluate the efficacy of oral panobinostat in patients with refractory/relapsed classical HL who have received prior treatment with high dose chemotherapy and autologous stem cell transplant. Safety of panobinostat will also be assessed. Other markers that may correlate with efficacy or safety will be explored. Recruiting 14 Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/14-hodgkin-s-lymphoma 1335 http://clinicaltrials.dfhcc.harvard.edu/trials/1335 Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma This is a Phase 1, single-arm, open-label, multi-center study designed to determine an effective and well-tolerated dose and schedule of pralatrexate when administered concurrently with vitamin B12 and folic acid supplementation to patients with relapsed or refractory CTCL. One cycle of treatment will be 3 or 4 weeks in duration, depending on treatment group. Treatment will continue until a patient meets criteria for discontinuation. Recruiting 14 Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/14-hodgkin-s-lymphoma 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma 1445 http://clinicaltrials.dfhcc.harvard.edu/trials/1445 Evaluating the Safety and Effectiveness of a Bone Marrow Transplant From Partially Matched Donors and Using Low Dose Chemotherapy in People With Leukemia or Lymphoma (BMT CTN #0603) Bone marrow transplants are one treatment option for people with leukemia or lymphoma. Family members or unrelated donors with a similar type of bone marrow usually donate their bone marrow to the transplant patients. This study will evaluate the effectiveness of a new type of bone marrow transplant—one that uses lower doses of chemotherapy and bone marrow donated from family members with only partially matched bone marrow—in people with leukemia or lymphoma. Recruiting 14 Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/14-hodgkin-s-lymphoma 11 Leukemia/MDS http://clinicaltrials.dfhcc.harvard.edu/diagnoses/11-leukemia-mds 17 Multiple Myeloma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/17-multiple-myeloma 15 Non-Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/15-non-hodgkin-s-lymphoma